Access to a novel first-line single-tablet HIV antiretroviral regimen in Affordable Care Act Marketplace plans, 2018–2020

Figures & data

Fig. 1 Coverage of DTG/ABC/3TC and BIC/FTC/TAF by Region and “Ending the HIV Epidemic” Status, 2020. Coverage of both medications was higher in the Northeast, compared to the Midwest, South and West. Coverage of both medications was lower among QHPs in the West compared to the other regions. A higher proportion of QHPs in EHE jurisdictions covered both medications compared to non-EHE jurisdictions

Fig. 2 Qualified Health Plan Coverage and Cost Sharing for DTG/ABC/3TC and BIC/FTC/TAF by Region, 2018–2020. Coverage of BIC/FTC/TAF increased in each of the regions, driven by coverage with coinsurance. DTG/ABC/3TC coverage was stable for QHPs in the Midwest, decreased slightly among the South, and increased for Northeast and West states

Fig. 3 Qualified Health Plan Coverage for DTG/ABC/3TC and BIC/FTC/TAF by “Ending the HIV Epidemic” Status, 2018–2020. Coverage of BIC/FTC/TAF increased in both EHE and non-EHE jurisdictions, driven by coverage with coinsurance

Fig. 4 Qualified Health Plan Coverage of DTG/ABC/3TC and BIC/FTC/TAF by State, 2018–2020. For each state, the y-axis reflects the proportion of qualified health plans offering coverage for either DTG/ABC/3TC and BIC/FTC/TAF. Coverage of both medications was consistently high in states like MD, DE, SC, and DC. Coverage of BIC/FTC/TAF increased in most states except for MS, ID, SC, and FL. The point values for each state-year are provided in Additional file 1: Table S1

Availability of data and materials

The data that support the findings of this study include publicly-available data from Robert Wood Johnson’s HIX Compare and data received from Ideon under a data use agreement. The data use agreement precludes our sharing of the data. Interested parties are referred to these two avenues to access the data.